Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cancer Therapies: The Breakthrough Era

This article was originally published in RPM Report

Executive Summary

FDA Office of Hematology & Oncology Products Director Richard Pazdur, MD, sat down to discuss the state of cancer R&D, Breakthrough therapies, and how his staff pushes to complete those speedy three-month reviews during The RPM Report’s FDA/CMS Summit for Biopharmaceutical Executives in December. Here is a transcript of the conversation, edited for clarity.


Related Content

FDA Responds to Nagging Questions About “Lagging” Drug Review Divisions
FDA Outlines “Expedited” Review For Breakthrough Therapies; “Hyper-Fast” Reviews, Beyond Oncology
FDA’s “Breakthrough” Evolves: What’s Next For The Popular Program?
Regressing to the Mean: FDA Innovative Drug Approvals Drop Back to “Normal” Levels
FDA “Program” Reviews Are Positive So Far, But Are They Sustainable?
Testing A New Model For Personalized Drug Development
FDA’s Pazdur Calls Accelerated Approval An “Interim Decision” With Ariad In Mind
Genentech’s Cancer Product Line Expands, As Do Its Post-Market Manufacturing Obligations





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts